IAM· Health Care› Biotechnology

Iambic Therapeutics, Inc.

$14.67

-6.86% today

$695M · Small cap

Market Neutral — Building

Pro read

Pro

Our read

Not enough history to read yet

Setup score

—

Momentum

—

Edge

—

Is IAM early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2026-10-15 → 2026-10-22

S? 1w

2026-10-152026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S? 1w current

Total tracked: 1 weeks across 1 stage run.

IAM among Biotechnology568th of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…568	IAMIambic Therapeutics, Inc.	—	—	—

vs 52W High

—

Stock is basing below old highs. A volume-backed breakout to new highs would be the Stage 2 signal to watch.

Stage Maturity

Week 2

1w13w26w

Week 2, fresh breakout

How long this stock has been basing. Longer bases can produce stronger breakouts, but the breakout itself is the signal.

vs 200 DMA

—

Stock is testing its 200 DMA as part of the base. Reclaiming and holding above it is a key Stage 2 prerequisite.

Rel Volume

—

vs 50-day avg

Volume in Stage 1 basing is typically quiet. A surge in volume on an upside breakout is the signal to watch.

Trend Health

—

Not enough history yet

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

—

YTD

—

Scan Membership

Not in any current scan.

Recent Stage Timeline

2026-10-22S—

Wk 2 · Vol —x

2026-10-21S—

Wk 1 · Vol —x

2026-10-20S—

Wk 1 · Vol —x

2026-10-19S—

Wk 1 · Vol —x

2026-10-16S—

Wk 1 · Vol —x

2026-10-15S—

Wk 1 · Vol —x

Moving averages & range

50 DMA

—

200 DMA

—

52W High

—

52W Low

—

5D Low

$14.67

Resistance levels (recent highs)

20d High

—

60d High

—

120d High

—

250d High

—

Next resistance

Above all

Dividend Yield

0.00%

P/B -1.5

Iambic Therapeutics: quick answers

Which sector and industry is Iambic Therapeutics in?

Iambic Therapeutics is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Iambic Therapeutics, Inc. operates as a biotechnology company that develops therapeutics from its AI discovery platform that optimizes target product profiles and drug candidates in the United States and Internationally. It offers products, such as IAM-1363, a selective HER2 inhibitor; IAM-K1, a KIF18A inhibitor; IAM217 (a KIF18A inhibitor) and IAM-C1, a CDK2/4 inhibitor; and services, including drug discovery platform and molecular superintelligence platform which includes technologies, such as Enchant and NeuralPLexer to design and develop small molecule therapeutics. Iambic Therapeutics, Inc. was formerly known as Entos, Inc. and changed its name to Iambic Therapeutics, Inc. in May 2023. The company was incorporated in 2019 and is based in San Diego, California.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.